Alzheimer's disease--from molecular biology to therapy.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Trends in Biotechnology

• Publication date

  1993-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0167-7799(93)90014-ZPMID 7765310
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• A computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase.

  2015cites this paper
• (+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.

  2011cites this paper
• Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.

  2011cites this paper
• Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities.

  2010cites this paper
• Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities.

  2010cites this paper
• Synthesis of 10-Amino-5,6,7,9-tetrahydro-1-thia-4,9-diazacyclohepta[f]inden-8-one Derivatives using Schmit Reaction

  2009cites this paper
• A quarter century of advancing treatment for Alzheimer's disease with Leon J. Thal

  2008cites this paper
• Substitute Consent for Research Involving the Elderly: A Comparison Between Quebec and France

  2008cites this paper
• HIV-Related Research with Cognitively Impaired Persons

  2007cites this paper
• Neurochemical and neurobehavioral effects of ganstigmine (CHF2819), a novel acetylcholinesterase inhibitor, in rat prefrontal cortex: an in vivo study.

  2007cites this paper
• Neuropathological and Immunochemical Studies of Brain Parenchyma in Acetylcholinesterase Knockout Mice: Implications in Alzheimer's Disease

  2007cites this paper
• Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.

  2006cites this paper
• Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial

  2006cites this paper
• Asymmetries in global-local processing ability in elderly people with the apolipoprotein E-ε4 allele

  2005cites this paper
• Drugs that target cholinesterases

  2004cites this paper
• Long-Term Cholinesterase Inhibitor Treatment of Alzheimer’s Disease

  2004cites this paper
• The Participation of Cognitively Impaired Elderly in Research

  2004cites this paper
• Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25-35)-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice.

  2002cites this paper
• Economic considerations of Alzheimer’s disease and related disorders

  2001cites this paper
• Blood—Brain Barrier

  2001cites this paper
• Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders

  2001cites this paper
• Velnacrine thiaanalogues as potential agents for treating Alzheimer's disease.

  2001cites this paper
• Treatment of Alzheimer's disease with cholinesterase inhibitors.

  2001cites this paper
• Effect of a Memory‐Enhancing Drug, AIT‐082, on the Level of Synaptophysin

  2000cites this paper
• Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors.

  2000cites this paper
• Neuronal Nicotinic Receptor Deficits in Alzheimer Patients with the Swedish Amyloid Precursor Protein 670/671 Mutation

  2000cites this paper
• Comparison of donepezil-, tacrine-, rivastigmine-and metrifonateinduced central and peripheral cholinergically mediated responses in the rat

  2000cites this paper
• A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease

  2000influential citation
• Cholinesterase inhibitors, β‐amyloid precursor protein and amyloid β‐peptides in Alzheimer's disease

  2000cites this paper
• Neuronal apoptosis as a therapeutic target in neurodegenerative disease

  2000cites this paper
• Synthesis of dihydroxanthone derivatives and evaluation of their inhibitory activity against acetylcholinesterase: unique structural analogs of tacrine based on the BCD-ring of arisugacin.

  1999cites this paper
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw

  1999cites this paper
• Current and the near future medications for Alzheimer's disease: What can we expect from them?

  1999cites this paper
• Synthesis and UV Studies of A Small Library of 6-Aryl-4-hydroxy-2-pyrones. A Relevant Structural Feature for the Inhibitory Property of Arisugacin Against Acetylcholinesterase

  1999cites this paper
• Muscarinic receptor ligands and their therapeutic potential.

  1999cites this paper
• Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?

  1998cites this paper
• The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling.

  1998cites this paper
• The neuropathological diagnosis of Alzheimer disease.

  1998cites this paper
• Invited Review Cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications

  1998cites this paper
• Metrifonate affects the peak interval performance in the rat

  1998cites this paper
• Neuropathology of Alzheimer's disease: a critical update.

  1998cites this paper
• Design of sustained-release matrix systems for a highly water-soluble compound, ABT-089

  1997cites this paper
• Drugs used in Alzheimer's disease and neuroplasticity.

  1997cites this paper
• Truncated tau protein as a new marker for Alzheimer's disease.

  1994cites this paper